MARKET

LUMO

LUMO

Lumos Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.22
+0.46
+4.71%
After Hours: 10.14 -0.08 -0.78% 18:28 05/10 EDT
OPEN
9.82
PREV CLOSE
9.76
HIGH
10.25
LOW
9.64
VOLUME
31.86K
TURNOVER
--
52 WEEK HIGH
36.72
52 WEEK LOW
9.53
MARKET CAP
85.16M
P/E (TTM)
-5.7871
1D
5D
1M
3M
1Y
5Y
10-Q: LUMOS PHARMA, INC.
(EDGAR Online via COMTEX) -- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and...
Edgar Online - (EDG = 10Q, 10K) · 4d ago
Lumos Pharma EPS misses by $0.17
Lumos Pharma (LUMO): Q1 GAAP EPS of -$1.04 misses by $0.17.Cash and cash equivalents of $114.1MPress Release
Seekingalpha · 5d ago
Lumos Pharma Q1 EPS $(1.04) Misses $(0.87) Estimate
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.87) by 19.54 percent. This is a 642.86 percent decrease over losses of $(0.14) per share from
Benzinga · 5d ago
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
Newly released PK/PD data from prior study in PGHD support endogenous LUM-201 MOA and use of Predictive Enrichment Markers (PEMs) to identify patients likely...
GlobeNewswire · 5d ago
Press Release: Lumos Pharma Reports First Quarter -2-
Dow Jones · 5d ago
Lumos Pharma Inc to Host Earnings Call
May 05, 2021 (ACCESSWIRE via COMTEX) -- NEW YORK, NY / ACCESSWIRE / May 5, 2021 / Lumos Pharma Inc (NASDAQ:LUMO) will be discussing their earnings results in...
ACCESSWIRE · 5d ago
Earnings Scheduled For May 5, 2021
  Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter.
Benzinga · 5d ago
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.
Benzinga · 05/01 17:19
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LUMO. Analyze the recent business situations of Lumos Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LUMO stock price target is 31.86 with a high estimate of 51.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 115
Institutional Holdings: 6.04M
% Owned: 72.46%
Shares Outstanding: 8.33M
TypeInstitutionsShares
Increased
7
59.71K
New
13
95.50K
Decreased
12
19.09K
Sold Out
4
1.57K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.01%
Pharmaceuticals & Medical Research
-0.44%
Key Executives
Chairman/President/Chief Executive Officer/Director
Richard Hawkins
Chief Financial Officer
Carl Langren
Chief Executive Officer
Brad Powers
Chief Operating Officer/Chief Scientific Officer
John McKew
Senior Vice President - Finance/Chief Accounting Officer/Controller
Lori Lawley
General Counsel
Bradley Powers
Other
Aaron Schuchart
Lead Director/Independent Director
Thomas Raffin
Director
An van Es-Johansson
Director
Nicholas Vahanian
Director
Joe McCracken
Independent Director
Emmett Cunningham
Independent Director
Chad Johnson
Independent Director
Kevin Lalande
Independent Director
Joseph McCracken
Independent Director
Lota Zoth
No Data
  • All
  • Financials
  • Insiders
More
About LUMO
Lumos Pharma, Inc., formerly NewLink Genetics Corporation, is a clinical stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for rare diseases. Its lead product candidate is LUM-201, an oral growth hormone stimulating therapeutic, is in late stage clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). LUM-201 is an orally administered small molecule that promotes the secretion (secretagogue) of Growth Hormone (GH) from the pituitary gland. LUM-201 acts as an agonist of the GH Secretagogue Receptor to stimulate GH release. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.

Webull offers kinds of Lumos Pharma Inc stock information, including NASDAQ:LUMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LUMO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LUMO stock methods without spending real money on the virtual paper trading platform.